Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Jonathan W Riess (ucdavis)

Description

Summary

This phase I trial tests the safety, side effects, and best dose of osimertinib, cetuximab, and tucatinib in treating patients with EFGR-mutant non-small cell lung cancer that is stage IV or has come back (recurrent). Osimertinib and tucatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets epidermal growth factor receptor (EGFR), a receptor overexpressed in many types of cancer, and may interfere with the ability of tumor cells to grow and spread. Giving osimertinib, cetuximab, and tucatinib may work better in treating patients with non-small cell lung cancer.

Official Title

A Phase I Study of Osimertinib, Cetuximab, and Tucatinib in Advanced EGFR-Mutant NSCLC With Acquired Resistance to Osimertinib

Details

Keywords

Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Carcinoma, Non-Small-Cell Lung Carcinoma, Cetuximab, Osimertinib, Tucatinib

Eligibility

Location

  • University of California Davis Comprehensive Cancer Center
    Sacramento California 95817 United States

Lead Scientist at University of California Health

  • Jonathan W Riess (ucdavis)
    Professor, MED: Int Med Hematology/Oncology, School of Medicine. Authored (or co-authored) 123 research publications

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
Jonathan Riess
ID
NCT06067776
Phase
Phase 1 research study
Study Type
Interventional
Participants
Expecting 36 study participants
Last Updated